Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era

Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era

Since pembrolizumab, an anti-programmed death-1 (PD-1) antibody, showed a dramatic response to immunogenic cancers with microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) in the pilot clinical trial KEYNOTE-016, subsequent studies have confirmed durable responses of anti...

Full description

Bibliographic Details
Main Authors: Keitaro Shimozaki, Izuma Nakayama, Toru Hirota, Kensei Yamaguchi
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cells
Subjects:
microsatellite instability
deficient mismatch repair
PD-1
gastrointestinal cancer
Online Access:https://www.mdpi.com/2073-4409/12/7/1049

Similar Items

Similar Items